Harrow Health Inc (HROW) shares surged 5.03% in pre-market trading on Wednesday, following a series of positive analyst reports that raised price targets for the company's stock. The surge comes as investors react to the bullish sentiment from Wall Street analysts.

H.C. Wainwright led the charge by increasing its price target on Harrow from $64 to $69, while maintaining a Buy rating. The firm cited a "robust" report from the company, although specific details were not provided. Similarly, Ladenburg analyst Jeffrey Cohen raised his price target to $66 from $64, also keeping a Buy rating on the shares. Lake Street reaffirmed its Buy rating on Harrow Health, further bolstering investor confidence.

These upgrades suggest that analysts are increasingly optimistic about Harrow Health's future prospects. The company, which specializes in the development, production, and sale of innovative ophthalmic products, appears to be impressing Wall Street with its performance and outlook. As investors digest these positive assessments, the stock's pre-market rally indicates growing enthusiasm for Harrow Health's potential in the healthcare sector.